Glaxo Smith Kline (GSK) is now having its experimental Ebola vaccine fast tracked towards human trials. The company is currently stockpiling on 10 thousand doses in order to be used for an emergency deployment. However, this will happen only if clinical test results are good.
The research is now accelerated thanks to funding offered by an international consortium. This is possible due to the current Ebola outbreak that hit West Africa.
The candidate vaccine is co-developed with the NIH. The trials are expected to be offered to volunteers that are healthy in the US and Great Britain in September. Phase I trials are programmed to begin as soon as regulatory and ethical approvals are received.
The NIH allergy and infections disease division is also working on a clinical trials program that includes another version of the GSK vaccine. It is meant to combat a new Ebola strain that appeared in the countries affected by the outbreak.
The US researchers are also planning a human test for a vaccine developed by government scientists in Canada. The vaccine was licensed to NewLink Genetics. Tests are meant to see if the drugs are safe for humans.